The ribosomal synthesis and enzymatic modifications of lantibiotics provide excellent opportunities to design and engineer a great variety of novel antimicrobial compounds.
Microbial secondary metabolites represent a significant source of potential drug leads; however, the majority of the corresponding biosynthetic genes are not expressed under normal laboratory conditions. In this review, we assess the capacity of exogenous small molecules, especially antibiotics, to activate these silent gene clusters.
Artemisinin resistance in Plasmodium falciparum malaria is causing failure of artemisinin-based combination therapies across an expanding area of Southeast Asia, undermining control and elimination efforts. The potential global consequences can only be avoided by new approaches that ensure sustained efficacy for antimalarial regimens in malaria affected populations.
The authors summarise current knowledge of prokaryotic glycobiology, focusing on structures and molecular details of biosynthesis concepts of glycoproteins and secondary cell-wall polymers, including their roles in prokaryotic life and their impact on pathogenicity as well as emerging glycoengineering strategies.
The authors review current research on the evolution and maintenance of microbial communication and cooperation from both a theoretical and experimental perspective.